CAS SIBS group improves synthesis of pristinamycin II by metabolic engineering

The group of JIANG Weihong at CAS SIBS in Shanghai achieved higher yields of pristinamycin, a S. pristinaespiralis antibiotic which can be used to treat MRSA infections, by an increase of gene copy numbers, metabolic engineering and absorption of the product in a macroporous resin. Yields were improved from 185 mg/L to over 1 g/L.

CAS news release, March 2, 2015

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny